Serum levels of neutrophil‐related IL‐6 and IL‐1β; GROα and IL‐18; angiogenesis‐related VEGF‐A and IL‐10; Th1‐related IFN‐γ, TNF‐α and IL‐12; Th17‐related IL‐17A and IL‐23; Th2‐related TARC, DEFB2 and IL‐13; and sepsis‐related PCT were reduced in patients with moderate‐to‐severe plaque psoriasis treated with secukinumab. This evidence concerns the gene CCL17 and Sepsis.